Editorial: Treating solid organ diseases with innovative chimeric-antigen receptor T-cells: current indications, progress, limitations and potential strategies.
| Autor: | Quackenbush E; Consultant, New York, NY, United States., Vijayaraghavan J; Department of Clinical Development, Viridian Therapeutics, Inc., Waltham, MA, United States., Ozay EI; Department of Immunology, Orbital Therapeutics, Inc., Cambridge, MA, United States., Ji RR; Department of Translational Medicine, Akamis Bio, Cambridge, MA, United States. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Frontiers in immunology [Front Immunol] 2024 Sep 24; Vol. 15, pp. 1491982. Date of Electronic Publication: 2024 Sep 24 (Print Publication: 2024). |
| DOI: | 10.3389/fimmu.2024.1491982 |
| Abstrakt: | Competing Interests: Author JV is employed by Viridian Therapeutics, Inc. Author EO was employed by Orbital Therapeutics, Inc. Author R-RJ was employed by Akamis Bio. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|